Definitive treatment of severe heart failure through myocardial regeneration therapy
First written in FY2024. 3 of 4 entries say "Restated". Latest entry: FY2027-H1.
No other company in this theme has enough history to compare yet.
- FY2027-H1RestatedAnnual report
「In terms of business conditions during the interim accounting period, development is continuing with the treatment program HS-001, involving open-chest administration of allogeneic iPS cell-derived myocardial spheres for patients with heart failure associated with ischemic heart disease, as the lead pipeline.」
Development of allogeneic iPS cell-derived myocardial spheres for patients with heart failure associated with ischemic heart disease is continuing, with HS-001 as the lead pipeline. - FY2025RestatedAnnual report
「Ｈｅａｒｔｓｅｅｄ株式会社 was established in November 2015 as a bio venture originating from Keio University School Corporation (hereinafter, "Keio University"). In the field of heart disease, the world's leading cause of death, the Company has adopted "Opening the door to heart disease treatment through regenerative medicine" as its mission and is pursuing the commercialization of myocardial regeneration therapy aimed at a definitive treatment for severe heart failure, one of the major diseases affecting the heart.」
The Company continues to identify the commercialization of myocardial regeneration therapy for severe heart failure as its mission. - FY2026-H1RestatedAnnual report
「In terms of business conditions during the interim accounting period, development is continuing with the treatment program HS-001, involving open-chest administration of allogeneic iPS cell-derived myocardial spheres for patients with heart failure associated with ischemic heart disease, as the lead pipeline.」
Development of allogeneic iPS cell-derived myocardial spheres for heart failure patients is continuing, with HS-001 as the lead pipeline. - FY2024First statedAnnual report
「With "Opening the door to heart disease treatment through regenerative medicine" as its mission, the Company is pursuing the commercialization of myocardial regeneration therapy aimed at a definitive treatment for severe heart failure, one of the major diseases affecting the heart.」
The Company positions the commercialization of myocardial regeneration therapy for severe heart failure as its raison d'être.